Table 1.

Expression of MAGE-A genes

Patients Pathology (according to the REAL classification)Fraction of MAGE-positive samples
B-cell NHL (n = 29)  Small lymphocytic lymphoma  0/2  
 Mantle cell lymphoma  0/5  
 Follicle center lymphoma  0/14 
 Marginal zone B-cell lymphoma  0/1  
 Diffuse large B-cell lymphoma  0/6  
 Plasmacytoma/plasma cell lymphoma 0/1  
 Total B-cell NHL  0/29  
T-cell NHL (n = 9) Precursor T-lymphoblastic lymphoma  0/3  
 Anaplastic large cell lymphomas  1/5* 
 Lymphoepithelioid peripheral T-cell lymphoma  1/1* 
 Total T-cell NHL  2/9 (22.2%)  
HD (n = 18)  Type I (lymphocyte predominance)  0/2  
 Type II (nodular sclerosis)  4/8* 
 Type III (mixed cellularity) 1/7* 
 Type IV (lymphocyte depletion)  0/1  
 Total HD  5/18 (27.8%) 
Patients Pathology (according to the REAL classification)Fraction of MAGE-positive samples
B-cell NHL (n = 29)  Small lymphocytic lymphoma  0/2  
 Mantle cell lymphoma  0/5  
 Follicle center lymphoma  0/14 
 Marginal zone B-cell lymphoma  0/1  
 Diffuse large B-cell lymphoma  0/6  
 Plasmacytoma/plasma cell lymphoma 0/1  
 Total B-cell NHL  0/29  
T-cell NHL (n = 9) Precursor T-lymphoblastic lymphoma  0/3  
 Anaplastic large cell lymphomas  1/5* 
 Lymphoepithelioid peripheral T-cell lymphoma  1/1* 
 Total T-cell NHL  2/9 (22.2%)  
HD (n = 18)  Type I (lymphocyte predominance)  0/2  
 Type II (nodular sclerosis)  4/8* 
 Type III (mixed cellularity) 1/7* 
 Type IV (lymphocyte depletion)  0/1  
 Total HD  5/18 (27.8%) 

Expression of MAGE-A genes was determined semiquantitatively with RT-PCR as explained in the legend to Figure 1.

*

Levels of expression of the individual MAGE-A genes in the positive samples were as follows: 1 anaplastic large cell lymphoma:MAGE-A1+, A2+, A3+, A4+, andA12+; 1 lymphoepithelioid cell lymphoma: MAGE-A4±; 4 HD type II: 1 MAGE-A4++ (HD4), 1 MAGE-A4+ (HD5), and 2MAGE-A4± (HD3, HD6); and 1 HD type III: MAGE-A4+ (HD17).

Close Modal

or Create an Account

Close Modal
Close Modal